Osanetant

Osanetant

Clinical data
ATC code	none
Identifiers
IUPAC name N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl]-N-methylacetamide
CAS Number	160492-56-8 Y
PubChem (CID)	219077
IUPHAR/BPS	2110
ChemSpider	189901 N
UNII	K7G81N94DT Y
ChEMBL	CHEMBL346178 N
ECHA InfoCard	100.233.307
Chemical and physical data
Formula	C35H41Cl2N3O2
Molar mass	606.625 g/mol
3D model (Jmol)	Interactive image
SMILES CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
InChI InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1 N Key:DZOJBGLFWINFBF-UMSFTDKQSA-N N
NY (what is this?)  (verify)

Osanetant (SR-142,801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which was being researched for the treatment of schizophrenia, but was discontinued.^[1][2] It was the first non-peptide NK₃ antagonist developed in the mid-1990s,^[3][4] Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.^[5][6]

References

1. ↑ "osanetant Sanofi-Aventis discontinued, France.". Highbeam. 
2. ↑ Kamali, F (July 2001). "Osanetant Sanofi-Synthélabo". Current opinion in investigational drugs (London, England : 2000). 2 (7): 950–6. PMID 11757797. 
3. ↑ Emonds-Alt, X; Bichon, D; Ducoux, JP; Heaulme, M; Miloux, B; Poncelet, M; Proietto, V; Van Broeck, D; et al. (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor". Life Sciences. 56 (1): PL27–32. doi:10.1016/0024-3205(94)00413-M. PMID 7830490. 
4. ↑ Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets. 7 (8): 975–92. doi:10.2174/138945006778019381. PMID 16918326. Retrieved 2011-04-14. 
5. ↑ Desouzasilva, M; Mellojr, E; Muller, C; Jocham, G; Maior, R; Huston, J; Tomaz, C; Barros, M (May 2006). "The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys". European Journal of Pharmacology. 536 (3): 269–78. doi:10.1016/j.ejphar.2006.03.010. PMID 16603151. 
6. ↑ Jocham, Gerhard; Lezoch, Katharina; Müller, Christian P.; Kart-Teke, Emriye; Huston, Joseph P.; De Souza Silva, M. AngéLica (September 2006). "Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core". European Journal of Neuroscience. 24 (6): 1721–32. doi:10.1111/j.1460-9568.2006.05041.x. PMID 17004936.